UCB Pharma Limited

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Fax: +44 (0) 1773 810644
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123
Patient Information Leaflet last updated on the eMC: 20/05/2009
PIL Xyzal 5 mg film-coated Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 20/05/2009 and displayed until Current
Reasons for adding or updating:
  • Change to how the medicine works
Updated on 20/02/2009 and displayed until 20/05/2009
Reasons for adding or updating:
  • Change to date of revision
Updated on 18/06/2008 and displayed until 20/02/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 17/04/2007 and displayed until 18/06/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 04/12/2006 and displayed until 17/04/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
  • Changes to therapeutic indications
Updated on 28/06/2006 and displayed until 04/12/2006
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 25/05/2005 and displayed until 28/06/2006
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 04/06/2003 and displayed until 25/05/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 20/01/2003 and displayed until 04/06/2003
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   levocetirizine dihydrochloride


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk